The evaluation of patients with essential thrombocythemia in terms of risk of thrombosis

Detalhes bibliográficos
Autor(a) principal: Sunu,Cenk
Data de Publicação: 2021
Outros Autores: Gunes,Ahmet Kursad, Akat,Gulten Korkmaz, Kalpakci,Yasin, Ceran,Funda, Dagdas,Simten, Ozet,Gulsum
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista da Associação Médica Brasileira (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021000400385
Resumo: SUMMARY OBJECTIVE: The aim of this study was to compare the incidence of factors associated with an increased risk of thrombosis in patients with essential thrombocythemia. METHODS: A total of 200 patients followed-up in our unit with a diagnosis of essential thrombocythemia in 13 years were analyzed retrospectively. RESULTS: Of the study participants, 60.5% were females and 39.5% were males, with an overall mean (±SD) age of 54.93 (±14.21) years. In 119 patients, Janus Kinase 2 was positive with 56.3% of cases. When two patient categories were defined as those with or without history of thrombosis, no significant differences were found in terms of Janus Kinase 2 positivity, mean age, as well as white blood cells and platelet counts (p>0.05). Also, no significant differences in thrombotic event incidence were found between patient categories defined on the basis of cut-off values for white blood cells (cut-off values of 15×103/mm3 and 8.7×103/mm3) and platelets (cut-off values of 1500×103/mm3) (p>0.05). CONCLUSION: Although our results are generally in line with the published data, some divergence from previous results has been observed with respect to risk factors for thrombotic events. Absence of a correlation between leukocytosis and thrombosis may be related with the significant decline in white blood cells after treatment. Also, a significant reduction in platelet counts occurring in association with treatment is linked with a lowered incidence of thrombosis. Janus Kinase 2-positive patients had a similar thrombosis frequency with that reported in the literature.
id AMB-1_afedae11e88a116ff7172b11e0bc7eff
oai_identifier_str oai:scielo:S0104-42302021000400385
network_acronym_str AMB-1
network_name_str Revista da Associação Médica Brasileira (Online)
repository_id_str
spelling The evaluation of patients with essential thrombocythemia in terms of risk of thrombosisThrombocythemia, essentialJanus kinase 2White blood cell countPlateletsThrombosisSUMMARY OBJECTIVE: The aim of this study was to compare the incidence of factors associated with an increased risk of thrombosis in patients with essential thrombocythemia. METHODS: A total of 200 patients followed-up in our unit with a diagnosis of essential thrombocythemia in 13 years were analyzed retrospectively. RESULTS: Of the study participants, 60.5% were females and 39.5% were males, with an overall mean (±SD) age of 54.93 (±14.21) years. In 119 patients, Janus Kinase 2 was positive with 56.3% of cases. When two patient categories were defined as those with or without history of thrombosis, no significant differences were found in terms of Janus Kinase 2 positivity, mean age, as well as white blood cells and platelet counts (p>0.05). Also, no significant differences in thrombotic event incidence were found between patient categories defined on the basis of cut-off values for white blood cells (cut-off values of 15×103/mm3 and 8.7×103/mm3) and platelets (cut-off values of 1500×103/mm3) (p>0.05). CONCLUSION: Although our results are generally in line with the published data, some divergence from previous results has been observed with respect to risk factors for thrombotic events. Absence of a correlation between leukocytosis and thrombosis may be related with the significant decline in white blood cells after treatment. Also, a significant reduction in platelet counts occurring in association with treatment is linked with a lowered incidence of thrombosis. Janus Kinase 2-positive patients had a similar thrombosis frequency with that reported in the literature.Associação Médica Brasileira2021-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021000400385Revista da Associação Médica Brasileira v.67 n.3 2021reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/1806-9282.20200778info:eu-repo/semantics/openAccessSunu,CenkGunes,Ahmet KursadAkat,Gulten KorkmazKalpakci,YasinCeran,FundaDagdas,SimtenOzet,Gulsumeng2021-08-24T00:00:00Zoai:scielo:S0104-42302021000400385Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2021-08-24T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false
dc.title.none.fl_str_mv The evaluation of patients with essential thrombocythemia in terms of risk of thrombosis
title The evaluation of patients with essential thrombocythemia in terms of risk of thrombosis
spellingShingle The evaluation of patients with essential thrombocythemia in terms of risk of thrombosis
Sunu,Cenk
Thrombocythemia, essential
Janus kinase 2
White blood cell count
Platelets
Thrombosis
title_short The evaluation of patients with essential thrombocythemia in terms of risk of thrombosis
title_full The evaluation of patients with essential thrombocythemia in terms of risk of thrombosis
title_fullStr The evaluation of patients with essential thrombocythemia in terms of risk of thrombosis
title_full_unstemmed The evaluation of patients with essential thrombocythemia in terms of risk of thrombosis
title_sort The evaluation of patients with essential thrombocythemia in terms of risk of thrombosis
author Sunu,Cenk
author_facet Sunu,Cenk
Gunes,Ahmet Kursad
Akat,Gulten Korkmaz
Kalpakci,Yasin
Ceran,Funda
Dagdas,Simten
Ozet,Gulsum
author_role author
author2 Gunes,Ahmet Kursad
Akat,Gulten Korkmaz
Kalpakci,Yasin
Ceran,Funda
Dagdas,Simten
Ozet,Gulsum
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Sunu,Cenk
Gunes,Ahmet Kursad
Akat,Gulten Korkmaz
Kalpakci,Yasin
Ceran,Funda
Dagdas,Simten
Ozet,Gulsum
dc.subject.por.fl_str_mv Thrombocythemia, essential
Janus kinase 2
White blood cell count
Platelets
Thrombosis
topic Thrombocythemia, essential
Janus kinase 2
White blood cell count
Platelets
Thrombosis
description SUMMARY OBJECTIVE: The aim of this study was to compare the incidence of factors associated with an increased risk of thrombosis in patients with essential thrombocythemia. METHODS: A total of 200 patients followed-up in our unit with a diagnosis of essential thrombocythemia in 13 years were analyzed retrospectively. RESULTS: Of the study participants, 60.5% were females and 39.5% were males, with an overall mean (±SD) age of 54.93 (±14.21) years. In 119 patients, Janus Kinase 2 was positive with 56.3% of cases. When two patient categories were defined as those with or without history of thrombosis, no significant differences were found in terms of Janus Kinase 2 positivity, mean age, as well as white blood cells and platelet counts (p>0.05). Also, no significant differences in thrombotic event incidence were found between patient categories defined on the basis of cut-off values for white blood cells (cut-off values of 15×103/mm3 and 8.7×103/mm3) and platelets (cut-off values of 1500×103/mm3) (p>0.05). CONCLUSION: Although our results are generally in line with the published data, some divergence from previous results has been observed with respect to risk factors for thrombotic events. Absence of a correlation between leukocytosis and thrombosis may be related with the significant decline in white blood cells after treatment. Also, a significant reduction in platelet counts occurring in association with treatment is linked with a lowered incidence of thrombosis. Janus Kinase 2-positive patients had a similar thrombosis frequency with that reported in the literature.
publishDate 2021
dc.date.none.fl_str_mv 2021-03-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021000400385
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021000400385
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1806-9282.20200778
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Médica Brasileira
publisher.none.fl_str_mv Associação Médica Brasileira
dc.source.none.fl_str_mv Revista da Associação Médica Brasileira v.67 n.3 2021
reponame:Revista da Associação Médica Brasileira (Online)
instname:Associação Médica Brasileira (AMB)
instacron:AMB
instname_str Associação Médica Brasileira (AMB)
instacron_str AMB
institution AMB
reponame_str Revista da Associação Médica Brasileira (Online)
collection Revista da Associação Médica Brasileira (Online)
repository.name.fl_str_mv Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)
repository.mail.fl_str_mv ||ramb@amb.org.br
_version_ 1754212836070916096